CONDITION

Immune-Mediated Haemolytic Anaemia (IMHA)

Immune-mediated haemolytic anaemia is a condition in which the body's immune system mistakenly identifies its own red blood cells as foreign and destroys them. This destruction happens faster than the bone marrow can replace the cells, leading to anaemia — a shortage of the oxygen-carrying cells the body depends on. It can appear suddenly or build more gradually, and may arise on its own or alongside other conditions. Owners often notice a combination of lethargy, pale or yellowish gums, faster breathing, or urine that looks darker than usual. Some dogs seem quieter than normal or tire quickly on walks that were previously manageable. The pattern of signs can vary, and the same outward picture may reflect different underlying processes. This page explores what these signs may indicate, the mechanisms that drive red cell destruction, the ways the condition is investigated through blood tests and imaging, and the range of approaches used to manage it. The aim is to help you understand what may be happening and what questions may be worth exploring.

Why this matters now

IMHA can present at any age but is most commonly recognised in young to middle-aged dogs, with a higher prevalence noted in certain breeds including Cocker Spaniels, English Springer Spaniels, Old English Sheepdogs, and Irish Setters. The condition may occur as a primary (idiopathic) autoimmune process or secondary to triggers such as infections, medications, neoplasia, or other immune-mediated diseases. Primary IMHA accounts for the majority of cases, though identifying and addressing any underlying trigger is an important part of the clinical picture. The onset can be remarkably rapid, with some dogs transitioning from apparently normal health to severe anaemia over the course of days.

The trajectory of IMHA can vary considerably between individuals. In its most acute form, red blood cell destruction outpaces the bone marrow's ability to produce replacements, leading to rapidly deepening anaemia with associated weakness, collapse, and cardiovascular compromise. The breakdown products of destroyed red blood cells — particularly bilirubin — may accumulate, producing jaundice and potentially dark or discoloured urine from haemoglobin or bilirubin excretion. A significant concern in IMHA is the predisposition to thromboembolic disease, where abnormal blood clotting occurs in vessels supplying vital organs, which can affect the lungs, liver, or other structures. Some dogs experience a more gradual course with a slower decline in red blood cell numbers, allowing more time for the bone marrow to mount a regenerative response. With immunosuppressive management, many dogs can achieve remission, though the risk of relapse means that long-term monitoring is typically part of the ongoing approach.

Signals & patterns

Early signals

Progressive lethargy and weakness

As red blood cell numbers decline, the body's capacity to deliver oxygen to tissues diminishes. Dogs may become noticeably less energetic, tiring more quickly on walks, being reluctant to play, or sleeping more than usual. This lethargy often progresses over days rather than weeks.

Pale gums and mucous membranes

The gums, inner eyelids, and other normally pink tissues may appear noticeably paler than usual as the circulating red blood cell volume drops. This pallor can range from light pink to almost white depending on the severity of the anaemia and is one of the most directly observable signs.

Increased respiratory rate at rest

As the blood's oxygen-carrying capacity decreases, the body compensates by increasing the breathing rate. Owners may notice their dog panting more than usual even at rest, or breathing more rapidly and shallowly in the absence of exercise or heat.

Reduced appetite

Many dogs with developing IMHA show a decline in interest in food. This may begin subtly with selective eating or leaving food in the bowl, progressing to more complete appetite loss as the anaemia deepens and the dog feels increasingly unwell.

Later signals

Jaundice (icterus)

As large numbers of red blood cells are destroyed, the released haemoglobin is metabolised to bilirubin, which can accumulate faster than the liver can process and excrete it. This produces a yellowish discolouration most visible in the whites of the eyes, the gums, the inner ear pinnae, and the skin of the abdomen. Jaundice indicates significant ongoing haemolysis.

Dark or discoloured urine

The breakdown products of red blood cell destruction — haemoglobin and bilirubin — may be excreted through the kidneys, producing urine that appears darker than normal, sometimes brown, reddish-brown, or orange. This discolouration reflects the degree of intravascular haemolysis occurring.

Rapid heart rate and bounding pulse

As anaemia becomes more severe, the cardiovascular system compensates by increasing heart rate and stroke volume to maintain oxygen delivery to tissues. A noticeably fast or strong heartbeat, sometimes visible or palpable through the chest wall, may develop alongside the other signs of advanced anaemia.

Click to read about the biological mechanisms

How this is usually investigated

Investigating suspected IMHA involves confirming the presence of anaemia, demonstrating that it is haemolytic in nature, and establishing evidence of immune-mediated destruction. Because IMHA can be secondary to other conditions, a thorough search for underlying triggers is also an important component of the diagnostic process.

Complete blood count (CBC) and blood smear

Purpose: A CBC quantifies the degree of anaemia and provides information about the bone marrow's regenerative response. Examination of a blood smear by a trained observer can reveal spherocytes (small, dense red blood cells that have lost part of their membrane during immune-mediated attack), polychromasia (indicating active red blood cell production), and auto-agglutination (clumping of red blood cells due to surface antibodies).
Considerations: The presence of spherocytes on a blood smear is one of the most supportive findings for IMHA, though they can also occur in other conditions. Auto-agglutination — where red blood cells visibly clump when a drop of blood is mixed with saline — is a particularly strong indicator of immune-mediated destruction. A regenerative anaemia (high reticulocyte count) suggests the bone marrow is responding appropriately to the increased red cell destruction, though some cases present with non-regenerative anaemia if the bone marrow is also affected.

Coombs test (direct antiglobulin test)

Purpose: The Coombs test detects antibodies or complement proteins bound to the surface of red blood cells, providing direct evidence that the immune system is targeting these cells. A positive result supports the diagnosis of IMHA, particularly when combined with compatible clinical and haematological findings.
Considerations: While a positive Coombs test strongly supports IMHA, false negatives can occur, particularly if the patient has already received immunosuppressive therapy. Conversely, weak positive results may occasionally occur in conditions other than IMHA. The test is most informative when interpreted alongside the complete clinical and laboratory picture rather than in isolation.

Biochemistry panel and urinalysis

Purpose: Serum biochemistry assesses organ function and may reveal elevated bilirubin levels reflecting the increased breakdown of haemoglobin. Liver and kidney parameters help evaluate secondary organ effects. Urinalysis may detect bilirubinuria or haemoglobinuria, providing additional evidence of haemolysis.
Considerations: Elevated bilirubin is expected in haemolytic conditions but can also occur with liver or biliary disease. Distinguishing between pre-hepatic (haemolytic), hepatic, and post-hepatic causes of hyperbilirubinaemia is an important part of the diagnostic process. Monitoring kidney function is relevant because haemoglobin released during intravascular haemolysis can potentially affect renal tubules.

Coagulation assessment

Purpose: Given the significant risk of thromboembolic complications in IMHA, assessment of coagulation status is often included in the diagnostic workup. This may include prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen levels, and D-dimer measurement to evaluate for evidence of disseminated intravascular coagulation (DIC) or hypercoagulability.
Considerations: Abnormal coagulation parameters in the context of IMHA may indicate developing DIC, which represents a serious complication. The coagulation profile helps guide decisions about anticoagulant therapy and monitoring intensity. D-dimer elevation, while non-specific, can support concerns about active thrombus formation.

Screening for underlying triggers

Purpose: Investigation for potential triggers of secondary IMHA may include infectious disease testing (tick-borne diseases such as Babesia, Ehrlichia, Anaplasma; blood-borne Mycoplasma species), imaging studies to screen for neoplasia, and review of recent medication or vaccination history.
Considerations: Identifying a secondary cause can significantly influence management approach and prognosis. Tick-borne disease testing is particularly important in endemic areas, as treatment of the underlying infection may reduce the immune stimulus driving red blood cell destruction. The absence of an identifiable trigger does not exclude secondary causes, as some triggers may be transient or difficult to detect retrospectively.

Options & trade-offs

Management of IMHA typically centres on suppressing the immune system's attack on red blood cells whilst supporting the patient through the period of severe anaemia. The approach is often intensive initially, with gradual reduction as the patient responds. The risk of thromboembolic complications adds an additional dimension to the management strategy.

Immunosuppressive therapy

The cornerstone of IMHA management involves medications that suppress the overactive immune response. Corticosteroids (typically prednisolone or dexamethasone) are usually the first-line immunosuppressive agents, often at high initial doses that are gradually tapered as the anaemia resolves. In cases that do not respond adequately to corticosteroids alone, additional immunosuppressive agents such as azathioprine, mycophenolate, ciclosporin, or leflunomide may be added.

Trade-offs: Corticosteroids produce predictable side effects including increased thirst, increased urination, increased appetite, panting, and muscle weakness, which can be substantial at the high initial doses required. The additional immunosuppressive agents each carry their own side effect profiles and drug interactions. Azathioprine requires monitoring for bone marrow suppression and hepatotoxicity. Mycophenolate can cause gastrointestinal effects. The duration of immunosuppressive therapy is typically months, with very gradual tapering guided by haematological monitoring, and some dogs require low-dose long-term therapy to prevent relapse.

Blood transfusion

When anaemia is severe enough to compromise oxygen delivery to vital organs, transfusion of packed red blood cells or whole blood may be necessary to stabilise the patient. Transfusions provide immediate improvement in oxygen-carrying capacity whilst immunosuppressive therapy takes effect, as the latter typically requires days to weeks to substantially reduce the rate of red blood cell destruction.

Trade-offs: Transfused red blood cells in a patient with active IMHA are subject to the same immune-mediated destruction as the patient's own cells, meaning their lifespan may be significantly shortened. Transfusion reactions, while managed through blood typing and crossmatching, remain a consideration. Multiple transfusions may be necessary in severe cases, and each subsequent transfusion carries an increased risk of transfusion reactions. The decision to transfuse balances the immediate need for improved oxygen delivery against these risks.

Antithrombotic therapy

Given the significant risk of thromboembolic complications in IMHA, antithrombotic therapy is often included as part of the management approach. This may involve antiplatelet agents, anticoagulants, or a combination, tailored to the individual patient's risk profile and coagulation status.

Trade-offs: Antithrombotic therapy aims to reduce the risk of life-threatening blood clots but must be balanced against the potential for haemorrhagic complications, particularly in an already anaemic patient. The optimal antithrombotic protocol for IMHA remains an area of active discussion in veterinary medicine, with different institutions favouring different approaches. Monitoring is required to assess both efficacy and safety of anticoagulation.

Splenectomy

In refractory cases that do not respond adequately to medical management, surgical removal of the spleen may be considered. The spleen is one of the primary sites where antibody-coated red blood cells are removed from circulation, so its removal can reduce the rate of red blood cell destruction in some patients.

Trade-offs: Splenectomy is typically reserved for cases that have failed to respond to immunosuppressive therapy, as medical management is effective in the majority of dogs. The procedure carries surgical risks that are increased in a severely anaemic patient, and the loss of the spleen's immune functions may increase susceptibility to certain infections. Not all patients respond to splenectomy, as the liver also contributes significantly to red blood cell removal in IMHA.

Common misconceptions

Misconception:

"IMHA is always caused by an identifiable trigger that can simply be removed"

Reality:

The majority of canine IMHA cases are classified as primary or idiopathic, meaning no specific trigger can be identified despite thorough investigation. While secondary IMHA does occur in response to identifiable triggers such as infections, medications, or neoplasia, the primary form represents a spontaneous failure of immune tolerance. This distinction is important because management of primary IMHA centres on immunosuppression rather than removal of an external cause, and the search for a trigger — while important — may not yield a definitive answer.

Misconception:

"Once a dog recovers from IMHA, the condition is permanently resolved"

Reality:

While many dogs achieve remission with appropriate immunosuppressive management, IMHA carries a meaningful risk of relapse. Relapse rates vary across studies but may occur in a substantial proportion of cases, sometimes months or years after initial resolution. This is why immunosuppressive therapy is typically tapered very gradually over months rather than stopped abruptly, and ongoing monitoring of haematological parameters continues well beyond the initial recovery period. Some dogs require low-dose maintenance immunosuppression indefinitely to prevent recurrence.

Misconception:

"A blood transfusion will fix the problem by replacing the destroyed red blood cells"

Reality:

While transfusion can be a necessary and life-saving intervention to stabilise a severely anaemic patient, it does not address the underlying immune process driving the destruction. Transfused red blood cells are subject to the same immune attack as the patient's own cells and may be destroyed relatively quickly. Transfusion provides a bridge — supporting the patient's oxygen-carrying capacity while immunosuppressive therapy takes effect — but it is the immunosuppression, not the transfusion, that addresses the root cause of the ongoing red blood cell destruction.

Related conditions

Babesiosis

Babesiosis destroys red blood cells directly and can trigger a secondary immune-mediated haemolysis, so it is excluded before a diagnosis of primary IMHA is settled, particularly in dogs with tick exposure or travel history.

Lymphoma in Dogs

Lymphoma is among the neoplastic conditions that can trigger secondary IMHA, and screening for underlying cancer forms part of the standard work-up in affected dogs.

Immune-Mediated Polyarthritis

Both conditions arise from misdirected immune attack on the body's own tissues, and they occasionally occur together or sequentially in dogs with immune-mediated disease.

Feline Leukaemia Virus (FeLV)

In cats, FeLV infection is a recognised trigger for immune-mediated red cell destruction, so retroviral status forms part of the anaemia work-up in this species.

IMHA is a condition where the speed of recognition and the depth of understanding can significantly influence the course. The combination of progressive lethargy, pale gums, and sometimes jaundice or dark urine forms a pattern that, once recognised, prompts a specific line of investigation. Understanding that the condition involves the body's own immune system attacking its red blood cells helps contextualise why the management approach focuses on immune modulation rather than simply replacing lost blood cells, and why the timeline for recovery typically extends over weeks to months with careful monitoring throughout.

Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS